These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20215909)

  • 1. The use and limitations of unfractionated heparin.
    Krishnaswamy A; Lincoff AM; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):35-40. PubMed ID: 20215909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
    Vardi M; Laor A; Bitterman H
    Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct thrombin inhibitors for anticoagulation.
    Nutescu EA; Wittkowsky AK
    Ann Pharmacother; 2004 Jan; 38(1):99-109. PubMed ID: 14742803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of heparin fractions: issues and answers.
    Messmore HL
    Crit Rev Clin Lab Sci; 1986; 23(2):77-94. PubMed ID: 2419035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo age dependency of unfractionated heparin in infants and children.
    Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
    Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Schmidt-Lucke C; Paar WD; Stellbrink C; Nixdorff U; Hofmann T; Meurer J; Grewe R; Daniel WG; Hanrath P; Mügge A; Klein HU; Schmidt-Lucke JA
    Thromb Res; 2007; 119(1):27-34. PubMed ID: 16443257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin in outpatient treatment of DVT.
    Yeager BF; Matheny SC
    Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous low molecular weight heparin for management of anticoagulation in infants on excor ventricular assist device.
    Ghez O; Liesner R; Karimova A; Ng C; Goldman A; van Doorn C
    ASAIO J; 2006; 52(6):705-7. PubMed ID: 17117062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation.
    Shalansky KF; FitzGerald JM; Sunderji R; Traboulay SJ; O'Malley B; McCarron BI; Naiman S
    Pharmacotherapy; 1996; 16(6):1076-84. PubMed ID: 8947981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.
    Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P
    Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.